The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)

PHASE4UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

April 1, 2024

Study Completion Date

July 31, 2025

Conditions
Coronary Artery Disease
Interventions
DRUG

Lansoprazole 15 mg

"1. Short-term treatment of active duodenal ulcer~2. Short-term treatment of active benign gastric ulcers~3. Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~4. Maintain duodenal ulcer after treatmentLaw~5. Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~6. Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~7. Short-term treatment of gastroesophageal reflux disease~8. Short-term treatment of erosive reflux esophagitis~9. Post-treatment maintenance therapy for erosive reflux esophagitis~10. Pathological hyperdivision, including Zolinger Ellison syndrome"

Sponsors
All Listed Sponsors
collaborator

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

lead

Daejeon St. Mary's hospital

OTHER